NPPA revises MRPs of 543 anti-cancer medicine brands, effective November 9
Synopsis
India's drug pricing authority has revised MRPs for 543 anti-cancer medicine brands, effective 9 November 2026 — the direct fallout of a trade margin rationalisation order covering 137 oncology drugs issued just 11 days earlier. With immunotherapy, Bevacizumab, Denosumab, and Pegfilgrastim among the covered medicines, this is one of the most sweeping oncology price interventions in recent years.
Key Takeaways
The NPPA released revised MRPs for 543 anti-cancer medicine brands on 28 October 2026 , effective 9 November 2026 .
The revision stems from NPPA's 17 October 2026 order rationalising trade margins on 137 non-scheduled anti-cancer medicines .
Key medicines covered include immunotherapy drugs for 20+ cancer types , Denosumab , Pegfilgrastim , and Bevacizumab .
Pricing data incorporated reflects manufacturer submissions up to 27 October 2026 ; the list will be updated continuously.
The full revised MRP list is available on the NPPA portal under the Department of Pharmaceuticals .
The National Pharmaceutical Pricing Authority (NPPA) on Wednesday, 28 October 2026, released a revised list of maximum retail prices (MRPs) for 543 brands of anti-cancer medicines, effective 9 November 2026. The revision follows the regulator's trade margin rationalisation initiative aimed at making cancer treatment more affordable and accessible across India.
What Changed and When It Takes Effect
The updated MRP list incorporates pricing data submitted by pharmaceutical companies up to 27 October 2026. The Ministry of Chemicals and Fertilizers confirmed that the list will be updated on a rolling basis as manufacturers submit revised prices for non-scheduled anti-cancer drugs.
'The revised MRPs will be effective from November 9, 2026,' the ministry stated, adding that the full list is accessible on the NPPA portal.
The Trade Margin Rationalisation Behind the Move
The revised MRPs flow directly from NPPA's announcement on 17 October 2026, when the authority rationalised trade margins on 137 non-scheduled anti-cancer medicines in the public interest. The initiative was designed to curb excessive markups across the pharmaceutical supply chain — a longstanding concern in oncology, where medicine costs can constitute the bulk of treatment expenses for patients.
Following that directive, manufacturers were required to submit revised price details to the regulator, which are now reflected in the expanded list of 543 brands.
Key Medicines Covered Under the Revision
The 137 medicines under the trade margin rationalisation exercise include several widely used cancer therapies. Among them:
Immunotherapy drugs prescribed for more than 20 types of cancer; Denosumab, used in the treatment of breast and prostate cancer; Pegfilgrastim, administered for the prevention of neutropenia in cancer patients; and Bevacizumab, approved for colon, ovarian, and cervical cancers.
What This Means for Patients and the Pharma Sector
For patients, the revisions represent a potential reduction in out-of-pocket costs at the retail level, particularly for those on long-term oncology regimens. India carries one of the highest cancer burdens globally, and drug affordability has consistently been flagged as a barrier to timely treatment.
For pharmaceutical companies, the ongoing submission process means pricing adjustments will continue beyond the initial 9 November effective date. The NPPA portal will reflect further revisions as additional manufacturers comply. The Department of Pharmaceuticals has underscored that the process is continuous, not a one-time fix.
With the revised list now public, regulators and civil society groups are expected to monitor whether retail prices at chemist counters align with the new MRPs — a gap that has historically undermined previous price-control exercises.
Point of View
Which is where oncology drug costs often balloon in India. However, the real test is enforcement at the retail end; previous price-control rounds have seen MRP revisions go unimplemented at chemist counters for weeks. With 543 brands and a rolling submission process, the risk of consumer confusion and non-compliance is real. Regulators will need active field monitoring, not just portal updates, to ensure patients see the benefit by 9 November.
NationPress
28 Oct 2026
Frequently Asked Questions
What has the NPPA announced regarding anti-cancer medicine prices?
The NPPA released revised MRPs for 543 brands of anti-cancer medicines on 28 October 2026, effective 9 November 2026. The revision follows a trade margin rationalisation exercise covering 137 non-scheduled oncology drugs announced on 17 October 2026.
Which anti-cancer medicines are covered under the trade margin rationalisation?
The 137 medicines include immunotherapy drugs prescribed for more than 20 types of cancer, Denosumab for breast and prostate cancer, Pegfilgrastim for neutropenia prevention, and Bevacizumab for colon, ovarian, and cervical cancers.
When will the revised cancer drug prices come into effect?
The revised MRPs will be effective from 9 November 2026. Pricing data in the current list reflects manufacturer submissions up to 27 October 2026, with further updates expected on a rolling basis.
What is trade margin rationalisation and why does it matter for patients?
Trade margin rationalisation caps the markup that distributors and retailers can charge over the manufacturer's price, targeting a key driver of high medicine costs in India. For cancer patients, who often face prolonged and expensive treatment regimens, reduced retail markups can meaningfully lower out-of-pocket expenses.
Where can patients and pharmacists access the revised MRP list?
The full list of 543 revised anti-cancer medicine brand MRPs is available on the NPPA portal under the Department of Pharmaceuticals. The portal will be updated continuously as additional manufacturers submit their revised pricing information.
